Artal Group’s Alpine Immune Sciences Inc ALPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-405,784
| Closed | -$16.1M | – | 132 |
|
|
2024
Q1 | $16.1M | Buy |
405,784
+355,025
| +699% | +$10.5M | 0.41% | 32 |
|
|
2023
Q4 | $967K | Sell |
50,759
-1,142,271
| -96% | -$15.9M | 0.03% | 73 |
|
|
2023
Q3 | $13.7M | Hold |
1,193,030
| – | – | 0.59% | 27 |
|
|
2023
Q2 | $12.3M | Hold |
1,193,030
| – | – | 0.38% | 38 |
|
|
2023
Q1 | $9.21M | Hold |
1,193,030
| – | – | 0.55% | 42 |
|
|
2022
Q4 | $8.77M | Hold |
1,193,030
| – | – | 0.49% | 47 |
|
|
2022
Q3 | $8.59M | Buy |
1,193,030
+600,000
| +101% | +$4.95M | 0.37% | 46 |
|
|
2022
Q2 | $5.05M | Hold |
593,030
| – | – | 0.27% | 59 |
|
|
2022
Q1 | $5.32M | Hold |
593,030
| – | – | 0.22% | 74 |
|
|
2021
Q4 | $8.21M | Hold |
593,030
| – | – | 0.22% | 75 |
|
|
2021
Q3 | $6.33M | Hold |
593,030
| – | – | 0.14% | 105 |
|
|
2021
Q2 | $5.34M | Hold |
593,030
| – | – | 0.11% | 115 |
|
|
2021
Q1 | $6.29M | Hold |
593,030
| – | – | 0.11% | 117 |
|
|
2020
Q4 | $7.47M | Hold |
593,030
| – | – | 0.16% | 96 |
|
|
2020
Q3 | $5.21M | Buy |
+593,030
| New | +$5.42M | 0.13% | 96 |
|
Artal Group's ALPN Position: Q2 2024 in Review
Artal Group sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 405,784 shares — an estimated $16.1M sold.
Artal Group first reported a position in ALPN in Q3 2020 and held it in 15 quarters. The position peaked at $16.1M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.
- Artal Group reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
- Artal Group sold 405,784 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $16.1M.
- Artal Group first reported a position in Alpine Immune Sciences Inc in Q3 2020 and held it in 15 quarters.
- Artal Group's Alpine Immune Sciences Inc position peaked at $16.1M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.
Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.